Zhang C, Liu Y, Li G, Yang Z, Han C, Sun X, et al. Targeting the undruggables-the power of protein degraders. Sci Bull. 2024;69:1776–97.

Article  CAS  Google Scholar 

Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, et al. Emerging pharmacotherapeutic strategies to overcome undruggable proteins in cancer. Int J Biol Sci. 2023;19:3360–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Song J, Zhou P, Zhou J, Xie S. Targeting undruggable transcription factors with PROTACs: Advances and perspectives. J Med Chem. 2022;65:10183–94.

Article  CAS  PubMed  Google Scholar 

Dale B, Cheng M, Park KS, Kaniskan H, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21:638–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Pang Q, Zhou J, Xuan C, Xie S. Leveraging aptamers for targeted protein degradation. Trends Pharmacol Sci. 2023;44:776–85.

Article  CAS  PubMed  Google Scholar 

Zhu H, Wang J, Zhang Q, Pan X, Zhang J. Novel strategies and promising opportunities for targeted protein degradation: an innovative therapeutic approach to overcome cancer resistance. Pharmacol Ther. 2023;244:108371.

Article  CAS  PubMed  Google Scholar 

Peng XP, Hu ZH, Zeng LM, Zhang MZ, Xu CC, Lu BY, et al. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies. Acta Pharm Sin B. 2024;14:533–78.

Article  CAS  PubMed  Google Scholar 

Song J, Hu M, Zhou J, Xie S, Li T, Li Y. Targeted protein degradation in drug development: Recent advances and future challenges. Eur J Med Chem. 2023;261:115839.

Article  CAS  PubMed  Google Scholar 

Zhang R, Xie S, Ran J, Li T. Restraining the power of proteolysis targeting chimeras in the cage: A necessary and important refinement for therapeutic safety. J Cell Physiol. 2024;239:e31255.

Article  CAS  PubMed  Google Scholar 

Huang D, Zou Y, Huang H, Yin J, Long S, Sun W, et al. A PROTAC augmenter for photo-driven pyroptosis in breast cancer. Adv Mater. 2024;36:e2313460.

Article  PubMed  Google Scholar 

Cai Z, Yang Z, Li H, Fang Y. Research progress of PROTACs for neurodegenerative diseases therapy. Bioorg Chem. 2024;147:107386.

Article  CAS  PubMed  Google Scholar 

Chen M, Zhou P, Kong Y, Li J, Li Y, Zhang Y, et al. Inducible degradation of oncogenic nucleolin using an aptamer-based PROTAC. J Med Chem. 2023;66:1339–48.

Article  CAS  PubMed  Google Scholar 

Kong L, Meng F, Wu S, Zhou P, Ge R, Liu M, et al. Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC. Clin Transl Med. 2023;13:e1191.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7:113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin J, Jin J, Shen Y, Zhang L, Gong G, Bian H, et al. Emerging protein degradation strategies: Expanding the scope to extracellular and membrane proteins. Theranostics. 2021;11:8337–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kong L, Meng F, Zhou P, Ge R, Geng X, Yang Z, et al. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer. Sci Bull. 2024;69:2122–35.

Article  CAS  Google Scholar 

Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584:291–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn G, Banik SM, Miller CL, Riley NM, Cochran JR, Bertozzi CR. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol. 2021;17:937–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noblejas-López MDM, Tébar-García D, López-Rosa R, Alcaraz-Sanabria A, Cristóbal-Cueto P, Pinedo-Serrano A, et al. Tackling cancer by targeting selective protein degradation. Pharmaceutics. 2023;15:2442.

Article  PubMed  PubMed Central  Google Scholar 

Miao Y, Gao Q, Mao M, Zhang C, Yang L, Yang Y, et al. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes. Angew Chem Int Ed Engl. 2021;60:11267–71.

Article  CAS  PubMed  Google Scholar 

Wu Y, Lin B, Lu Y, Li L, Deng K, Zhang S, et al. Aptamer-LYTACs for targeted degradation of extracellular and membrane proteins. Angew Chem Int Ed Engl. 2023;62:e202218106.

Article  CAS  PubMed  Google Scholar 

Li Y, Liu X, Yu L, Huang X, Wang X, Han D, et al. Covalent LYTAC enabled by DNA aptamers for immune checkpoint degradation therapy. J Am Chem Soc. 2023;145:24506–21.

CAS  Google Scholar 

Tian Y, Miao Y, Guo P, Wang J, Han D. Insulin-like growth factor 2-tagged aptamer chimeras (ITACs) modular assembly for targeted and efficient degradation of two membrane proteins. Angew Chem Int Ed Engl. 2024;63:e202316089.

Article  CAS  PubMed  Google Scholar 

Duan Q, Jia HR, Chen W, Qin C, Zhang K, Jia F, et al. Multivalent aptamer-based lysosome-targeting chimeras (LYTACs) platform for mono- or dual-targeted proteins degradation on cell surface. Adv Sci. 2024;11:e2308924.

Article  Google Scholar 

Pance K, Gramespacher JA, Byrnes JR, Salangsang F, Serrano JC, Cotton AD, et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat Biotechnol. 2023;41:273–81.

Article  CAS  PubMed  Google Scholar 

Wang Q, Yang X, Yuan R, Shen A, Wang P, Li H, et al. A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation. Nat Commun. 2024;15:1663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang K, Yu A, Liu K, Feng C, Hou Y, Chen J, et al. Nano-LYTACs for degradation of membrane proteins and inhibition of CD24/Siglec-10 signaling pathway. Adv Sci. 2023;10:e2305364.

Article  Google Scholar 

Zhang B, Brahma RK, Zhu L, Feng J, Hu S, Qian L, et al. Insulin-like growth factor 2 (IGF2)-fused lysosomal targeting chimeras for degradation of extracellular and membrane proteins. J Am Chem Soc. 2023;145:24272–83.

Article  CAS  PubMed  Google Scholar 

Su LY, Tian Y, Zheng Q, Cao Y, Yao M, Wang S, et al. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor. Cell Chem Biol. 2024;31:1219–30.

Article  CAS  PubMed  Google Scholar 

Liu ZQ, Deng QQ, Qin G, Yang J, Zhang HC, Ren JS, et al. Biomarker-activated multifunctional lysosome-targeting chimeras mediated selective degradation of extracellular amyloid fibrils. Chem-US. 2023;9:2016–38.

Article  CAS  Google Scholar 

Huang Y, Zhou X, Zhang Y, Xie M, Wang F, Qin J, et al. A nucleic acid-based LYTAC plus platform to simultaneously mediate disease-driven protein downregulation. Adv Sci. 2024;11:e2306248.

Article